Lundbeck’s experimental therapy, asedebart, brought cortisol levels back to normal in most adults with Cushing’s disease and was generally well tolerated when given as an intravenous (into-the-vein) infusion, according to preliminary data from the first part of an ongoing Phase 2 clinical trial. The BalanCeD (NCT06471829) study,…
News
Treatment with Korlym (mifepristone) may help lower blood sugar and promote weight loss in people with hard-to-control diabetes and high cortisol levels who are also taking medications targeting GLP-1, according to a new analysis of data from dozens of patients in the CATALYST clinical trial. Corcept Therapeutics, the…
Crinetics Pharmaceuticals, along with several patient groups, has launched the Everyday Advocacy initiative to help people with Cushing’s syndrome and other endocrine, or hormone-related, conditions better understand their diseases and take an active role in their care. Developed with input from several advocacy partners — including the…
Mutations in the USP8 gene appear to switch on a signaling pathway, called Sonic Hedgehog (SHH), in pituitary tumors that cause Cushing’s disease, according to a study involving patient tumor data and laboratory cell experiments. These results suggest that targeting this pathway could help guide future treatment research for patients…
After an unrelated medical exam revealed a mass on a man’s right adrenal gland, further testing showed his symptoms were actually caused by Cushing’s disease, rooted in a small pituitary tumor in the brain, according to a case report. The case highlights the need for careful testing to find…
A Moroccan woman with Cushing’s syndrome caused by prolonged exposure to glucocorticoids was unexpectedly found to also have Cushing’s disease, the form driven by a tumor in the brain’s pituitary gland, a case report shows. After stopping treatment with glucocorticoids, also commonly called corticosteroids or steroids, her cortisol levels…
Improvements in quality of life after successful surgery for Cushing’s disease vary widely, with many patients continuing to struggle physically and emotionally in the months following treatment despite normalization of cortisol levels, a new study has found. “Our results highlight the need to educate and support patients before and…
Japan’s Ministry of Health, Labour and Welfare has granted orphan drug designation to Lundbeck’s asedebart, an investigational therapy for Cushing’s disease and congenital adrenal hyperplasia (CAH), two conditions characterized by excessive production of adrenocorticotropic hormone. This regulatory status is intended to support the development of medicines for serious rare…
A father and daughter who carried the same genetic variant both developed Cushing’s disease, according to a recent report. Both underwent pituitary surgery through the nose, called an endoscopic endonasal approach, followed by glucocorticoid replacement therapy, and both remain in biochemical remission. Researchers still do not know whether the…
Abnormal protein levels in the blood that develop during Cushing’s disease may somewhat, but not entirely, normalize when disease activity resolves, a new study reports. These “distinct [blood] protein profiles” could potentially indicate an “increased risk for thrombosis [formation of a blood clot inside a blood vessel] and metabolic…
Recent Posts
- Asedebart normalizes cortisol levels in most Cushing’s patients: Data
- My Cushing’s disease brain fog has a mind of its own
- Korlym improves results for diabetes patients taking GLP-1 drugs
- New ‘Everyday Advocacy’ initiative supports Cushing’s syndrome care
- Intersecting identities: The similarities in being queer and chronically ill
- Sonic Hedgehog pathway may be target in Cushing’s disease
- Incidental adrenal mass leads to man’s Cushing’s diagnosis: Report
- What a Cushing’s disease flare-up looks like for me
- Rare case study details double Cushing’s syndrome/disease diagnosis
- Quality of life improvements vary widely after Cushing’s disease surgery